BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 16931630)

  • 1. Expression of tumor-associated antigens in acute myeloid leukemia: Implications for specific immunotherapeutic approaches.
    Greiner J; Schmitt M; Li L; Giannopoulos K; Bosch K; Schmitt A; Dohner K; Schlenk RF; Pollack JR; Dohner H; Bullinger L
    Blood; 2006 Dec; 108(13):4109-17. PubMed ID: 16931630
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Elevated expression of the leukemia-associated antigen SSX2IP predicts survival in acute myeloid leukemia patients who lack detectable cytogenetic rearrangements.
    Guinn B; Greiner J; Schmitt M; Mills KI
    Blood; 2009 Jan; 113(5):1203-4. PubMed ID: 19179477
    [No Abstract]   [Full Text] [Related]  

  • 3. WT1, PRAME, and PR3 mRNA Expression in Acute Myeloid Leukemia (AML).
    Steger B; Floro L; Amberger DC; Kroell T; Tischer J; Kolb HJ; Schmetzer HM
    J Immunother; 2020; 43(6):204-215. PubMed ID: 32502139
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Leukemic progenitor cells are susceptible to targeting by stimulated cytotoxic T cells against immunogenic leukemia-associated antigens.
    Schneider V; Zhang L; Rojewski M; Fekete N; Schrezenmeier H; Erle A; Bullinger L; Hofmann S; Götz M; Döhner K; Ihme S; Döhner H; Buske C; Feuring-Buske M; Greiner J
    Int J Cancer; 2015 Nov; 137(9):2083-92. PubMed ID: 25912930
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification and characterization of epitopes of the receptor for hyaluronic acid-mediated motility (RHAMM/CD168) recognized by CD8+ T cells of HLA-A2-positive patients with acute myeloid leukemia.
    Greiner J; Li L; Ringhoffer M; Barth TF; Giannopoulos K; Guillaume P; Ritter G; Wiesneth M; Döhner H; Schmitt M
    Blood; 2005 Aug; 106(3):938-45. PubMed ID: 15827130
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cancer vaccines for patients with acute myeloid leukemia--definition of leukemia-associated antigens and current clinical protocols targeting these antigens.
    Greiner J; Döhner H; Schmitt M
    Haematologica; 2006 Dec; 91(12):1653-61. PubMed ID: 17145602
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dendritic cells generated from acute myeloid leukemia (AML) blasts maintain the expression of immunogenic leukemia associated antigens.
    Li L; Reinhardt P; Schmitt A; Barth TF; Greiner J; Ringhoffer M; Döhner H; Wiesneth M; Schmitt M
    Cancer Immunol Immunother; 2005 Jul; 54(7):685-93. PubMed ID: 15627212
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Frequent T cell responses against immunogenic targets in lung cancer patients for targeted immunotherapy.
    Babiak A; Steinhauser M; Götz M; Herbst C; Döhner H; Greiner J
    Oncol Rep; 2014 Jan; 31(1):384-90. PubMed ID: 24154794
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The tumor-associated antigen RHAMM (HMMR/CD168) is expressed by monocyte-derived dendritic cells and presented to T cells.
    Willemen Y; Van den Bergh JM; Bonte SM; Anguille S; Heirman C; Stein BM; Goossens H; Kerre T; Thielemans K; Peeters M; Van Tendeloo VF; Smits EL; Berneman ZN
    Oncotarget; 2016 Nov; 7(45):73960-73970. PubMed ID: 27659531
    [TBL] [Abstract][Full Text] [Related]  

  • 10. mRNA expression of leukemia-associated antigens in patients with acute myeloid leukemia for the development of specific immunotherapies.
    Greiner J; Ringhoffer M; Taniguchi M; Li L; Schmitt A; Shiku H; Döhner H; Schmitt M
    Int J Cancer; 2004 Feb; 108(5):704-11. PubMed ID: 14696097
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chronic myeloid leukemia cells express tumor-associated antigens eliciting specific CD8+ T-cell responses and are lacking costimulatory molecules.
    Schmitt M; Li L; Giannopoulos K; Chen J; Brunner C; Barth T; Schmitt A; Wiesneth M; Döhner K; Döhner H; Greiner J
    Exp Hematol; 2006 Dec; 34(12):1709-19. PubMed ID: 17157168
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cancer-testis antigen expression and its epigenetic modulation in acute myeloid leukemia.
    Atanackovic D; Luetkens T; Kloth B; Fuchs G; Cao Y; Hildebrandt Y; Meyer S; Bartels K; Reinhard H; Lajmi N; Hegewisch-Becker S; Schilling G; Platzbecker U; Kobbe G; Schroeder T; Bokemeyer C; Kröger N
    Am J Hematol; 2011 Nov; 86(11):918-22. PubMed ID: 21898529
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-time RT-PCR quantification of PRAME gene expression for monitoring minimal residual disease in acute myeloblastic leukaemia.
    Tajeddine N; Millard I; Gailly P; Gala JL
    Clin Chem Lab Med; 2006; 44(5):548-55. PubMed ID: 16681423
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [PRAME mRNA expression in newly diagnosed acute myeloid leukemia patients and its application to monitoring minimal residual disease].
    Qin YZ; Li JL; Zhu HH; Li LD; Chang Y; Hao L; Wang YZ; Jiang B; Lu XJ; Liu YR; Huang XJ; Chen SS
    Zhonghua Xue Ye Xue Za Zhi; 2008 Jul; 29(7):441-5. PubMed ID: 19035174
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictive value of pretransplantation molecular minimal residual disease assessment by WT1 gene expression in FLT3-positive acute myeloid leukemia.
    Candoni A; De Marchi F; Zanini F; Zannier ME; Simeone E; Toffoletti E; Chiarvesio A; Cerno M; Filì C; Patriarca F; Fanin R
    Exp Hematol; 2017 May; 49():25-33. PubMed ID: 28159598
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression patterns of WT1 and PRAME in acute myeloid leukemia patients and their usefulness for monitoring minimal residual disease.
    Qin Y; Zhu H; Jiang B; Li J; Lu X; Li L; Ruan G; Liu Y; Chen S; Huang X
    Leuk Res; 2009 Mar; 33(3):384-90. PubMed ID: 18950857
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Receptor for hyaluronan acid-mediated motility (RHAMM) is a new immunogenic leukemia-associated antigen in acute and chronic myeloid leukemia.
    Greiner J; Ringhoffer M; Taniguchi M; Schmitt A; Kirchner D; Krähn G; Heilmann V; Gschwend J; Bergmann L; Döhner H; Schmitt M
    Exp Hematol; 2002 Sep; 30(9):1029-35. PubMed ID: 12225794
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aberrant hypomethylation of the cancer-testis antigen PRAME correlates with PRAME expression in acute myeloid leukemia.
    Ortmann CA; Eisele L; Nückel H; Klein-Hitpass L; Führer A; Dührsen U; Zeschnigk M
    Ann Hematol; 2008 Oct; 87(10):809-18. PubMed ID: 18587578
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High prognostic value of pre-allogeneic stem cell transplantation minimal residual disease detection by WT1 gene expression in AML transplanted in cytologic complete remission.
    Candoni A; De Marchi F; Zannier ME; Lazzarotto D; Filì C; Dubbini MV; Rabassi N; Toffoletti E; Lau BW; Fanin R
    Leuk Res; 2017 Dec; 63():22-27. PubMed ID: 29096332
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epigenetic regulation of PRAME in acute myeloid leukemia is different compared to CD34+ cells from healthy donors: effect of 5-AZA treatment.
    Gutierrez-Cosío S; de la Rica L; Ballestar E; Santamaría C; Sánchez-Abarca LI; Caballero-Velazquez T; Blanco B; Calderón C; Herrero-Sánchez C; Carrancio S; Ciudad L; Cañizo C; San Miguel JF; Pérez-Simón JA
    Leuk Res; 2012 Jul; 36(7):895-9. PubMed ID: 22503131
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.